Fund facts

Fund size*

$46.0m
Base currency
USD
Listing date
23 Jan 2018
Domicile
Ireland
Index ticker
SOLBIOT
Replication method
Physical - backed by equities

Statistics

*As at 28 Sep 2023

Fund aim

The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").

Long-term allocation

Long-term value in a pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives

High growth potential

Aims to capture the future growth opportunity in orphan drugs

Leveraging industry expertise

An index tracking investment strategy that is supported by a team of pharmaceutical experts

Does it have a sustainable objective?

The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.

Further details

Charges and taxTER
0.49%
ISA eligible
Yes
SIPP eligible
Yes
UK Fund Reporting Status
Yes

Management / administration

Issuer

Legal & General UCITS ETF Plc

Depositary and Trustee

The Bank of New York Mellon SA/NV, Dublin Branch

Securities regulator

Central Bank of Ireland

Country registration

This share class is registered for sale in the following countries:

Listings

Details

Codes

Exchange	Currency	Ticker	Listing date	ISIN	Bloomberg	Reuters	Trading hours (local)
London Stock Exchange	GBP	BIGT	23/01/2018	IE00BF0H7608	BIGT LN	BIGT.L	08:00 - 16:30
London Stock Exchange	USD	BIOT	23/01/2018	IE00BF0H7608	BIOT LN	GEBIOT.L	08:00 - 16:30
Borsa Italiana	EUR	BIOT	23/02/2018	IE00BF0H7608	BIOT IM	ECBIOT.MI	09:00 - 17:30
Deutsche Börse Xetra	EUR	ETLI	06/02/2018	IE00BF0H7608	ETLI GY	ETLI.DE	09:00 - 17:30
Euronext Amsterdam	EUR	BIOT	01/02/2018	IE00BF0H7608	BIOT NA	GOBIOT.AS	09:00 - 17:30
SIX Swiss Exchange	CHF	BIOT	05/06/2020	IE00BF0H7608	BIOT SW	BIOTC.S	09:00 - 17:30

Solactive Pharma Breakthrough Value Index

The Index is comprised of bio-technology companies which are publicly traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An “orphan drug” is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publicly traded) and (2) it is sufficiently “liquid” (a measure of how actively its shares are traded on a daily basis).

The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.

Index dataProvider
Solactive
Bloomberg code
SOLBIOT
Reuters code
.SOLBIOT
Type
Net Total Return
Website
www.solactive.com

Fund updates

Performance

Source: Lipper.

Performance for the USD Accumulating ETF class in USD, listed on 23 January 2018. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.

Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past. The tables and charts above shows the fund's performance as the percentage loss or gain per year over the last 10 years.

Performance (%)

Change

Performance summary (%)

To month-end
To quarter-end

As at 31 Aug 2023

Cumulative	Fund	Benchmark
1 month	-2.42	-2.39
6 months	-5.69	-5.62
Year to date	-6.70	-6.57
3 years	-12.95	-11.88
5 years	-2.06	0.31
Since launch	9.58	-

Annualised	Fund	Benchmark
1 year	0.99	1.36
3 years	-4.52	-4.13
5 years	-0.42	0.06
Since launch	-	-

As at 30 Jun 2023

Cumulative	Fund	Benchmark
Quarterly	-3.52	-3.43
Year to date	-7.44	-7.37
3 years	-9.35	-8.23
5 years	9.13	11.87
Since launch	8.72	-

Annualised	Fund	Benchmark
1 year	-1.30	-0.94
3 years	-3.22	-2.82
5 years	1.76	2.27
Since launch	-	-

Rolling 12-month performance

Calendar year performance

Monthly performance

Annualised performance

Rolling 12-month performance to last quarter end (%)

	Fund	Benchmark
2014	-	-
2015	-	-
2016	-	-
2017	-	-
2018	-	-
2019	-0.98	-0.28
2020	21.59	22.25
2021	10.71	11.32
2022	-17.04	-16.78
2023	-1.30	-0.94

12 months to 30 June	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Fund	-	-	-	-	-	-0.98	21.59	10.71	-17.04	-1.30
Benchmark	-	-	-	-	-	-0.28	22.25	11.32	-16.78	-0.94

Calendar year performance (%)

	Fund	Benchmark
2013	-	-
2014	-	-
2015	-	-
2016	-	-
2017	-	-
2018	-	-
2019	12.67	13.45
2020	27.09	27.73
2021	-3.85	-3.44
2022	-7.26	-6.86

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Fund	-	-	-	-	-	-	12.67	27.09	-3.85	-7.26
Benchmark	-	-	-	-	-	-	13.45	27.73	-3.44	-6.86

Monthly performance (%)

To month-end
To quarter-end

Annualised performance (%)

	1 year	3 years	5 years	Since launch
Fund	0.99	-4.52	-0.42	-
Benchmark	1.36	-4.13	0.06	-

Annualised performance (%)

	1 year	3 years	5 years	Since launch
Fund	-1.30	-3.22	1.76	-
Benchmark	-0.94	-2.82	2.27	-

Portfolio

As at 31 Aug 2023. All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding.

The breakdowns shown relate to the Index. The ETF’s portfolio may deviate from the portfolio of the Index.

Sector (%)

Health Care

100.0

USD	62.4
JPY	17.7
HKD	6.1
EUR	3.9
DKK	3.7
AUD	3.2
SEK	3.1

	Top 10 constituents	37.7
	Rest of Index	62.3

No. of constituents in Index

Top 10 constituents (%)

Chugai Pharmaceutical	4.3
Vertex Pharmaceuticals	4.2
Eisai	4.0
Ipsen	3.9
Genmab	3.7
Astrazeneca	3.6
Horizon Therapeutics	3.6
Nippon Shinyaku	3.5
Biogen	3.5
Jazz Pharmaceuticals	3.4

Country (%)

	United States	55.4
	Japan	17.7
	Ireland	7.0
	Cayman Islands	6.1
	France	3.9
	Denmark	3.7
	Australia	3.2
	Sweden	3.1

Investment Manager

The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.

LGIMIndex Fund Management Team

Sustainability-related Disclosures

SFDR categorisation: Article 9Article 9: These funds have a sustainable investment objective

Download SFDR Product Summary Download LGIME PAI entity report

Sustainable investment objective
ESG investment strategy
Sustainability preferences

Environmental characteristics

Social characteristics

The sustainable investment objective of the Fund is to provide exposure to the global orphan drugs industry. The Fund and seeks to achieve its investment objective by tracking the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.

The Fund follows the following sustainability-related investment strategy by tracking the Index that applies:

Battery Value-Chain Theme

Clean Water Theme

Clean Energy Theme

Hydrogen Economy Theme

Healthcare Breakthrough Theme

Pharma Breakthrough Theme

The Index is comprised of bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs that treat rare diseases.

Companies eligible for inclusion in the Index universe shall be determined based on industry classification data provided by an independent third-party provider of consensus forecasts of leading industry analysts and analysis of the pharmaceutical and biotechnology healthcare sectors. In order to be eligible for inclusion in the Index a company must have a minimum of two marketed orphan drugs and must derive a proportion of revenue from orphan drugs which is within the top two quartiles of relevant orphan drugs companies, as determined by an independent third-party provider.

Having assessed the existing constituents of the Index, we have concluded that such investments do not significantly harm any environmental and social objectives. We have implemented processes and checks, using both environmental and social indicators, to verify on a bi-annual basis that the Fund’s investments do not cause any significant harm to any such objectives.

Green Bonds

RAFI ESG Score

RAFI Exclusions

Solactive PAB Optimisation

Solactive Exclusions

Net Zero

SDG Alignment

Carbon Emissions Intensity Target

LGIM ESG Score

LGIM's Future World Protection List

LGIM's Climate Impact Pledge

Foxberry Paris Aligned

MSCI Exclusions

MSCI ESG Score

JPM Exclusions

JPM ESG Score

Additional Exclusions

ESG Factor Evaluation

Decarbonisation

LGIM Coal Policy

LGIM Controversial Weapons

J.P. Morgan ESG Exclusions

J.P. Morgan ESG Score

FTSE ESG Exclusions

ROBO Global ESG Policy

Solactive ESG Exclusions

Solactive ESG Enhanced Exclusions

The Index excludes companies which

are non-compliant with the UN Global Compact,
are associated with a controversy (i.e. companies that have been involved in events that have a severe impact on the environment and society, posing serious business risks to the company),
are involved in the production or retail of tobacco, or are a related product/service,
are involved in military contracting weapons or related products,
are directly involved or indirectly involved through corporate ownership, in controversial weapons,
are involved in the retail or distribution of small arms to civilians (assault and non-assault weapons) and military/law enforcement customers, as well as key components of small arms,
are involved in thermal coal extraction, power generation or increase the power generation capacity of coal
are involved in the generation, production or increase the capacity of conventional oil and gas, or supporting products/services,
are involved in oil sands extraction, arctic oil & gas exploration/extraction, shale energy extraction or increase the capacity of unconventional oil & gas,
are involved in the production, distribution, supporting products or capacity increase of nuclear power,
are involved in the production, retail or related services/products of alcohol,
are involved in the operations, specialized equipment or supporting products/services of gambling, and
are involved in the production or distribution of adult entertainment.

The ESG Exclusions Enhanced Index is monitored on an on-going basis and updated regularly by the index provider. Such exclusions and the definition of “involvement” are determined by the Index provider by reference to the “ESG Exclusions Enhanced Index" which is found at: https://solactive.com/downloads/Guideline-Solactive-ESG-Exclusions-Enhanced-Index.pdf

Nasdaq ESG Exclusions

Stoxx Exclusions

Taxonomy

The Fund does not invest a minimum amount in economic activities that qualify as environmentally sustainable under the Taxonomy Regulation.

Sustainable Investments

The Fund will invest at least 90% of its portfolio in investments that qualify as sustainable, all of which provide direct exposure to investee companies. The Fund will invest at least 0% of its portfolio in environmentally sustainable investments and at least 90% of its portfolio in socially sustainable investments. The actual level of environmentally and socially sustainable investments held by the Fund will always equate to at least the minimum proportion of sustainable investments of the portfolio outlined above. Some of the sustainable investments may be considered to contribute to both environmental and social objectives. The remaining portion of investments are not used to meet the sustainable investment objective.

Further information on LGIM's Sustainable Investment Methodology can be found here.

Principal Adverse Impacts

The Fund considers principal adverse impacts on sustainability factors and LGIM has identified a subset of the adverse sustainability indicators that are relevant to the Fund’s investments. The Fund considers principal adverse impacts, identified using the below listed sustainability indicators, through the implementation of the Fund’s ESG investment strategy.

PAI 10: Companies violating UNGC/OECD

Literature

Key literature

First Addendum to Prospectus

Fact sheets

2023Change date

Marketing documents

Thematic ETFs performance report

31 Mar 2023

Legal documents

First Addendum to Prospectus

28 Nov 2022

Fund schedule supplement

28 Nov 2022

Fund supplement

16 Mar 2023

MiFID II EMT Costs and Charges

31 Aug 2023

MiFID II EPT Costs and Charges

15 Dec 2022

Supplementary information document

01 Nov 2021

Constitution

20 Apr 2020

ESG reports

2023Change date

Execution venues

2020Change date

Top 5 Execution Venues Report

30 Apr 2020

Top 5 Execution Venues Report

30 Apr 2019

Top 5 Execution Venues Report Data

30 Apr 2020

Top 5 Execution Venues Report Data

30 Apr 2019

Reports and accounts

2022Change date

Annual Report and Accounts

30 Jun 2022

Annual Report and Accounts

30 Jun 2021

Annual Report and Accounts

30 Jun 2020

Annual Report and Accounts

30 Jun 2019

Annual Report and Accounts

30 Jun 2018

Interim Report and Accounts

31 Dec 2022

Interim Report and Accounts

31 Dec 2021

Interim Report and Accounts

31 Dec 2020

Interim Report and Accounts

31 Dec 2019

Interim Report and Accounts

31 Dec 2018

Interim Report and Accounts

31 Dec 2017

Reportable income

2022Change date

Trading information

Dealing day calendar

28 Sep 2023

Best execution & order handling policy

01 Feb 2022

Dealing deadlines

27 Sep 2023

Fund valuation points

27 Sep 2023

iNav codes summary

27 Sep 2023

Shareholder notices

2022Change date

ICSD transition announcement

20 Apr 2020

ICSD transition FAQs

23 Mar 2020

Results of Sanction Hearing

20 Mar 2020

Change in Management Company

13 Mar 2020

Change of Investment Manager

14 Oct 2021

Results of Scheme Meeting and EGM

Prices

Name

USD Acc

Currency

USD

NAV

10.25

Price time

16:00 EST (NY)

Key risks

The value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested.

Past performance is not a guide to the future.

An investment in the ETF involves a significant degree of risk. Any decision to invest should be based on the information contained in the relevant prospectus. Prospective investors should obtain their own independent accounting, tax and legal advice and should consult their own professional advisers to ascertain the suitability of the ETF as an investment.

The value of the shares in the ETF is directly affected by increases and decreases in the value of the Index. Accordingly the value of a share in the ETF may go up or down and a shareholder may lose some or the entire amount invested.

The ETF's ability to closely track the Index will be affected by its ability to purchase and/or sell the Index constituents and any legal or regulatory restrictions or disruptions affecting them.

The ETF's ability to closely track the Index will also be affected by transaction costs and taxes incurred when adjusting its investment portfolio generally and/or to mirror any periodic adjustments to the constituents of the Index. There can be no certainty that ETF shares can always be bought or sold on a stock exchange or that the market price at which the ETF shares may be traded on a stock exchange will reflect the performance of the Index.

The ETF is subject to the risk that third party service providers (such as a bank entering into swaps with the ETF or the ETF's depositary) may go bankrupt or fail to pay money due to the ETF or return property belonging to the ETF.

As the Index includes micro, small and medium-sized publicly traded companies, the ETF is subject to the risk that such companies may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies or the stock market as a whole.

Companies that are actively engaged in the research, development and manufacture of orphan drugs are particularly vulnerable to the risk that, following lengthy and costly development periods, a drug may not ultimately enter into revenue-generating commercial production as a result of: (i) clinical trial failures, (ii) governmental intervention or refusal to grant appropriate approvals and/or licenses for clinical trials or commercial production and/or (iii) a lack of commercially viability. Additionally, the emergence of cheaper or more effective drugs could lead to a decline in the revenues of such companies. Such factors could lead to a decline in the value of the companies represented in the Index and therefore the ETF.

For more information, please refer to the key investor information document.

Important information

In the United Kingdom and outside the European Economic Area, it is issued by Legal & General Investment Management Limited, authorised and regulated by the Financial Conduct Authority, No. 119272. Registered in England and Wales No. 02091894 with registered office at One Coleman Street, London, EC2R 5AA.

In the European Economic Area, it is issued by LGIM Managers (Europe) Limited, authorised by the Central Bank of Ireland as a UCITS management company (pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (S.I. No. 352 of 2011), as amended) and as an alternative investment fund manager with “top up” permissions which enable the firm to carry out certain additional MiFID investment services (pursuant to the European Union (Alternative Investment Fund Managers) Regulations 2013 (S.I. No. 257 of 2013), as amended). Registered in Ireland with the Companies Registration Office (No. 609677). Registered Office: 70 Sir John Rogerson’s Quay, Dublin, 2, Ireland. Regulated by the Central Bank of Ireland (No. C173733).

LGIM Managers (Europe) Limited operates a branch network in the European Economic Area, which is subject to supervision by the Central Bank of Ireland. In Italy, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Commissione Nazionale per le società e la Borsa (“CONSOB”) and is registered with Banca d’Italia (no. 23978.0) with registered office at Via Uberto Visconti di Modrone, 15, 20122 Milan, (Companies’ Register no. MI - 2557936). In Germany, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the German Federal Financial Supervisory Authority (“BaFin”). In the Netherlands, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Dutch Authority for the Financial Markets (“AFM“) and it is included in the register held by the AFM and registered with the trade register of the Chamber of Commerce under number 74481231. Details about the full extent of our relevant authorisations and permissions are available from us upon request.

We are a member of the Irish Funds Association.

All features described on this website are those current at the time of publication and may be changed in the future. Nothing on this website should be construed as advice and it is therefore not a recommendation to buy or sell securities. If in doubt about the suitability of this product, you should seek professional advice. Copies of the prospectus, key investor information document, annual and semi-annual reports & accounts are available free of charge on request or at www.lgimetf.com.

This website is only directed at investors resident in jurisdictions where our funds are registered for sale. It is not an offer or invitation to persons outside of those jurisdictions. We reserve the right to reject any applications from outside of such jurisdictions.

Source and third party data

Source: Unless otherwise indicated all data contained on this website is sourced from Legal & General Investment Management Limited.

Where this document contains third party data ('Third Party Data’), we cannot guarantee the accuracy, completeness or reliability of such Third Party Data and accept no responsibility or liability whatsoever in respect of such Third Party Data

Index disclaimer

The L&G Pharma Breakthrough UCITS ETF (the “ETF”) is not sponsored, promoted, sold or supported by Solactive AG. Nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trade mark or the Index price, at any time or in any other respect.

The Solactive Pharma Breakthrough Value Index (the “Index”) is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Legal & General UCITS ETF Plc, Solactive AG has no obligation to point out errors in the Index to third parties including, but not limited to, investors and/or financial intermediaries of the ETF. Solactive AG does not guarantee the accuracy and/or the completeness of the Index or any related data, and shall not have any liability for any errors, omissions or interruptions therein.

Neither publication of the Index by Solactive AG, nor the licensing of the Index or Index trade mark, for the purpose of use in connection with the ETF, constitutes a recommendation by Solactive AG to invest capital in said ETF nor does it, in any way, represent an assurance or opinion of Solactive AG with regard to any investment in this ETF. In no event shall Solactive AG have any liability for any lost profits or indirect, punitive, special or consequential damages or losses, even if notified of the possibility thereof.

L&G Pharma Breakthrough UCITS ETF

Fund facts

Statistics

Fund aim

Fund snapshot

Further details

Charges and tax

Management / administration

Country registration

Listings

Solactive Pharma Breakthrough Value Index

Index data

Fund updates

Performance

Performance summary (%)

Rolling 12-month performance to last quarter end (%)

Calendar year performance (%)

Monthly performance (%)

Annualised performance (%)

Annualised performance (%)

Portfolio

Sector (%)

Currency (%)

Top 10 constituents (%)

Country (%)

Investment Manager

Sustainability-related Disclosures

Literature

Key literature

Fact sheets

Marketing documents

Legal documents

ESG reports

Execution venues

Reports and accounts

Reportable income

Trading information

Shareholder notices

Prices

Key risks

Important information

Source and third party data

Index disclaimer